New hope for hard-to-treat lymphoma: first human trial of LTZ-301 begins
NCT ID NCT07121946
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug is shrinking tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
-
Memorial Sloan Kettering Cancer Center - Bergen
RECRUITINGNew York, New York, 10065, United States
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Pronged attack beat brain lymphoma?
- Can a new drug combo outsmart resistant lymphomas?
- Can a targeted drug boost standard chemo for aggressive lymphoma?
- Can a targeted drug combo outsmart an aggressive lymphoma?
- Can a reshaped chemo combo tame lymphoma with fewer side effects?
- Can a chemo-free cocktail tame mantle cell lymphoma?